The validation of Integrated Testing Strategies for skin sensitisation:
Presented by Martyn Chilton at the 2017 SOT Annual Meeting.
There has been a large amount of research in recent years towards the development of alternatives to in vivo assays for assessing the potential of chemicals to cause skin sensitisation. This has been driven by regulations such as REACH and legislation such as the European Cosmetics Directive, alongside ethical and societal concerns around animal testing. It is generally recognised that a single in vitro assay will not be sufficient to replace the current gold standard in vivo assay, the murine Local Lymph Node Assay (LLNA). As such a number of Integrated Testing Strategies (ITS) have been developed (henceforth referred to more generally as defined approaches to testing and assessment). These aim to integrate data from a number of sources (e.g. in silico, in chemico, in vitro) to make better predictions of skin sensitisation hazard potential and/or potency, in the absence of in vivo data.